Tectonic Therapeutic (TECX) Price & Analysis

Compare

549 Followers

TECX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$13.70 - $61.07

Previous CloseN/A

Volume30.18K

Average Volume (3M)234.43K

Market Cap

$420.69M

Enterprise Value$248.18K

Total Cash (Recent Filing)$306.25M

Total Debt (Recent Filing)$2.63M

Price to Earnings (P/E)―

Beta1.31

Next Earnings

Nov 06, 2025

EPS Estimate

-1.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.07

Shares Outstanding18,672,508

10 Day Avg. Volume219,841

30 Day Avg. Volume234,434

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-0.94

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$81.50

Price Target Upside271.81% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessFull Phase Ib TX45 data reinforced the striking interim data, which provided a clear clinical POC for the relaxin class and signaled that a significant 6MWT benefit will likely be observed in Phase II – an approvable Phase III endpoint.

Financial PositionTectonic's financial position is robust, with $306.2M in cash expected to support operations for several years.

Market PotentialThe potential of TX45 in pulmonary hypertension is considered underappreciated, which indicates room for positive market surprises.

Bears Say

Historical ChallengesHistorical relaxin-targeted therapies in cardiovascular disease have previously failed or were terminated.

Valuation ConcernsValuation disconnect is influenced by Eli Lilly's earlier discontinuation of a similar program, raising doubts on the relaxin class as a whole.

Tectonic Therapeutic News

Tectonic Therapeutic initiated with a Buy at Truist

Truist initiated coverage of Tectonic Therapeutic (TECX) with a Buy rating and $64 price target Tectonic is advancing...

18d ago

TECX

Promising Outlook for Tectonic Therapeutic: Strategic Differentiation and Market Opportunities

Leerink Partners analyst David Risinger has maintained their bullish stance on TECX stock, giving a Buy rating yesterday....

5h ago

TECX

Tectonic Therapeutic Inc. Reports Increased Cash Reserves

Tectonic Therapeutic Inc ( ($TECX) ) has released its Q2 earnings. Here is a breakdown of the information...

9h ago

TECX

Tectonic Therapeutic Reports Q2 Financial Results

The latest announcement is out from Tectonic Therapeutic ( ($TECX) ). On August 7, 2025, Tectonic Therapeutic announced...

17h ago

TECX

Closing Bell Movers: Merit Medical Systems gains after Q2 outlook

In the opening hour of the evening session, U.S. equity futures are down again following a post-holiday session...

1M ago

BIIB

MMSI

Tectonic Therapeutic files $400M mixed securities shelf

17:50 EDT Tectonic Therapeutic (TECX) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

1M ago

TECX

Tectonic Therapeutic joins Russell 3000 Index

Tectonic Therapeutic (TECX) announced that it has been added to the broad-market Russell 3000 Index. Tectonic’s addition follows...

1M ago

TECX

Tectonic Therapeutic resumed with an Outperform at Raymond James

Raymond James resumed coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $76 price target as part...

2M ago

TECX

Tectonic Therapeutic Holds 2025 Annual Stockholders Meeting

Tectonic Therapeutic ( ($TECX) ) has provided an update. On June 6, 2025, Tectonic Therapeutic, Inc. held its...

2M ago

TECX

Tectonic Therapeutic initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $87 price target Published first...

2M ago

TECX

Tectonic Therapeutic’s TX45: A Promising Solution for Unmet Medical Needs in Pulmonary Hypertension

Cory Jubinville, PhD, an analyst from LifeSci Capital, has initiated a new Buy rating on Tectonic Therapeutic (TECX)....

2M ago

TECX

Tectonic Therapeutic Reports Q1 2025 Financial Results

Tectonic Therapeutic Inc ( ($TECX) ) has released its Q1 earnings. Here is a breakdown of the information...

2M ago

TECX

Promising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45

Leerink Partners analyst David Risinger has maintained their bullish stance on TECX stock, giving a Buy rating on...

3M ago

TECX

Tectonic Therapeutic Announces Phase 1b Trial Results

Tectonic Therapeutic ( ($TECX) ) has shared an update. On May 17, 2025, Tectonic Therapeutic announced the complete...

3M ago

TECX

TECX FAQ

What was Tectonic Therapeutic’s price range in the past 12 months?

Tectonic Therapeutic lowest stock price was $13.70 and its highest was $61.07 in the past 12 months.

What is Tectonic Therapeutic’s market cap?

Tectonic Therapeutic’s market cap is $420.69M.

When is Tectonic Therapeutic’s upcoming earnings report date?

Tectonic Therapeutic’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.

How were Tectonic Therapeutic’s earnings last quarter?

Tectonic Therapeutic released its earnings results on Aug 07, 2025. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.977 by -$0.093.

Is Tectonic Therapeutic overvalued?

According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tectonic Therapeutic pay dividends?

Tectonic Therapeutic does not currently pay dividends.

What is Tectonic Therapeutic’s EPS estimate?

Tectonic Therapeutic’s EPS estimate is -1.03.

How many shares outstanding does Tectonic Therapeutic have?

Tectonic Therapeutic has 18,672,508 shares outstanding.

What happened to Tectonic Therapeutic’s price movement after its last earnings report?

Tectonic Therapeutic reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.977. Following the earnings report the stock price went down -5.354%.

Which hedge fund is a major shareholder of Tectonic Therapeutic?

Currently, no hedge funds are holding shares in TECX

Tectonic Therapeutic Stock Smart Score

Neutral

Fundamentals

Return on Equity

-30.10%

Trailing 12-Months

Asset Growth

240.92%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tectonic Therapeutic

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.

Tectonic Therapeutic (TECX) Earnings & Revenues

Historic Earnings Reports

TECX Stock 12 Month Forecast

Average Price Target

$81.50

▲(271.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","36":"$36","58":"$58","80":"$80","102":"$102"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$101.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$81.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$64.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,36,58,80,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.73,26.904615384615383,33.07923076923077,39.253846153846155,45.428461538461534,51.60307692307693,57.777692307692305,63.952307692307684,70.12692307692308,76.30153846153846,82.47615384615385,88.65076923076923,94.8253846153846,{"y":101,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.73,25.404615384615383,30.07923076923077,34.753846153846155,39.428461538461534,44.10307692307693,48.777692307692305,53.452307692307684,58.12692307692308,62.801538461538456,67.47615384615385,72.15076923076923,76.8253846153846,{"y":81.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.73,24.05846153846154,27.386923076923075,30.715384615384615,34.043846153846154,37.37230769230769,40.700769230769225,44.029230769230765,47.357692307692304,50.68615384615384,54.01461538461538,57.34307692307692,60.67153846153846,{"y":64,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.9,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.14,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >